MDCE Melanoma Scan Beta Volunteer Dataset Review
Analysis based on 23 articles · First reported Aug 31, 2026 · Last updated Sep 23, 2026
The announcements represent incremental development progress for a micro-cap OTC-listed company and are unlikely to materially move broader markets. Any market impact would be confined to speculative interest in Medical Care Technologies Inc. shares, with limited liquidity and no near-term revenue implications given the beta-stage, non-cleared status of the product.
Medical Care Technologies Inc. (OTCID:MDCE) announced a series of milestones in the development of its MDCE Melanoma Scan Beta platform, an AI-assisted imaging and body-map monitoring application. On August 31, 2026, the company announced it was seeking its first volunteers for human-submitted dataset testing, moving beyond training solely on public cancer imaging archives such as HAM10000, ISIC Archive collections, and TCIA melanoma cohorts. On September 4, 2026, the company confirmed that volunteer intake was active for the first human-submitted image cohort. On September 16, 2026, Medical Care Technologies Inc. announced it had received its first human volunteer image datasets, which entered internal review. On September 23, 2026, the company announced that internal review of those first volunteer-submitted image datasets was underway, focusing on image intake, body-map mapping, and change-over-time comparison. CEO Marshall Perkins characterized the receipt and review of volunteer data as major milestones. The platform remains in beta-stage development, has not received regulatory clearance, and is not intended to diagnose, treat, cure, or prevent any disease or medical condition.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard